4.1 Findings in Light of Existing Pricing Policies
The availability of price data is an indication for the market entry of medicines. Data from this study point to staggered marketing of medicines across countries (in the literature [
10,
17‐
20], this approach has been described as a ‘strategic launch’ of marketing authorisation holders). If price data are considered as proxy for the availability of a medicine on the market, the findings imply that in some European countries patients have to wait for months and years after marketing authorisation before they can access the medicine (if affordable). Delayed accessibility of new medicines in some European countries has also been shown in other research [
12,
19,
28‐
30].
A country’s income level is one of the commonly provided explanations for staggered market entry. As such, medicines are first launched in countries with high-income (gross domestic product) per inhabitant in which solidarity-based funding schemes are able to afford higher prices. Delayed launches in lower-income and lower-priced countries are attributed to the widespread existence of the EPR policy as this staggered market entry allows companies to delay a reduction in prices [
10,
17‐
20,
28‐
31]. In addition to a country’s income and its medicine price levels, population size can also constitute a cause for availability limitations (delayed availability or non-availability) or affordability issues (i.e. smaller countries, due to their smaller markets, have been confronted with higher prices) [
20,
28,
29,
32,
33]. Another factor is the extent and type of price regulation. From a marketing authorisation holder’s perspective, within the (current) EU, Germany and England are considered to be the most attractive markets since they do not apply traditional price control measures [
34] (in Germany, medicines can be brought on the market immediately after marketing authorisation, and prices are free during the first year [
22]; and England’s Pharmaceutical Price Regulation Scheme (PPRS) is designed as a profit control mechanism [
35]). Further administrative reasons, including the marketing authorisation procedure or delays in assessments, may also play a role [
29,
30,
36].
Overall, findings of this study suggest that medicines in countries with higher income and also higher medicine prices were launched earlier, compared with markets with lower income and medicine prices (the definition of price levels is based on the results of this analysis as well as further studies with a country basket of at least 15 of the 28 EU Member States [
37‐
39]
3 ). Germany, Austria and Denmark, high-income countries with high price levels, were among countries with early availability of price data and, assumingly, early availability of the medicines on the market, whereas price data were only available at later stages (in some cases even 3 or 5 years after marketing authorisation) in Greece and some Central and Eastern European countries. Research also showed delayed availability in smaller markets, such as the Baltic countries (Estonia, Latvia and Lithuania) and Cyprus. At the same time, a few small markets in higher-income countries (Luxembourg, Slovenia) had earlier availability. Furthermore, the results are mixed with regard to Portugal (hit hard by the global financial crisis a few years ago) and Romania (among the lowest-income countries of the EU), which could have been expected to have major delayed availability. However, this was not the case, suggesting multifactorial reasons (e.g. Romania being a large market). It would require a larger basket of medicines to test whether or not this pattern prevails.
The decreases in the average European prices appear to result from both the inclusion of lower prices in some reference countries in which price data were available at a later point in time, and price reductions in other countries. This indicates that from a cost-containment perspective, EPR-applying countries could also benefit from continuous price revisions and, in particular, at later stages. There is room for improvement for countries that refrain from regular price evaluations or solely perform price revisions in a rather short interval after the launch of the medicine. According to a 2015 survey, 25 of 30 EPR-applying European countries do price monitoring, thereof 17 on a regular basis, whereas the remainder perform ad hoc price revisions. The duration of the intervals was reported to range between 3 months to 5 years [
13].
In light of the limitations in access to and affordability of new medicines with high price tags, there have been discussions about the most appropriate pricing, as well as reimbursement and policies, both in research as well as at political levels [
4‐
9,
40]. There is no ‘one-size-fits-all’ solution as there are different policies with regard to different types of medicines (e.g. on-patent vs. off-patent), price types (e.g. ex-factory prices vs. pharmacy retail prices) and policy objectives (i.e. early access to medicines, financial sustainability of the healthcare system, reward for innovation). The policy objectives depend on national priorities of policymakers, and are sometimes conflicting. As a result, policymakers may need to opt for a mix of different policy options [
41,
42].
Policy options to ensure access to medicines also differ with regard to their feasibility and timelines. While some of them, for instance methodological changes in existing policies, are solutions in technical areas that can be implemented at short notice, others (e.g. collaborative approaches of countries to agree on principles of differential pricing or to do strategic procurement, or new funding mechanisms to simulate research and development) require high political commitment and can only be implemented in the long-term [
43].
A pragmatic approach could be that, while policymakers work on developing new policy options in the long-term, they implement feasible, practical measures in the short-term. One of the policy changes that aim to ensure financial sustainability of healthcare systems is an optimisation of the methodological design for EPR; this implies regular revisions. The findings of this study provide (although for only a few medicines) an evidence base that the European average prices continue decreasing, even months and years after marketing authorisation. Since the frequency of price revisions under the EPR policy, and further methodological issues, are either determined in technical methodology papers or are regulated in a decree or a law, at national levels, such measures can be implemented rather swiftly in a country, without consultation of other countries. Nonetheless, it should be considered that EPR, including price revisions, is rather resource-intensive, in particular if the country basket is large. However, since most countries do not survey price data for EPR but ask the marketing authorisation holder to submit the price data of the reference countries [
14], workload can be limited. In addition, improved collaboration between countries, such as through the price database Euripid, which is fed by pricing authorities of EU Member States [
44], helps reduce the resources required for regular price revisions.
4.2 Limitations
This study has several limitations. First, the research was performed for a sample of a few medicines and is not comprehensive. There is room for further research to investigate whether or not a larger sample would lead to the same findings. Second, data had to be imputed in a few cases in which retrospective price data gathering was not possible and these data had not been included in the PPI system earlier. Third, the selected medicines are likely to be subject to discounts and further price-reducing arrangements, such as risk-sharing agreements and other managed entry agreements between the marketing authorisation holder and the public payer in several countries [
3,
45‐
50]. List prices were taken instead of actual discounted prices since the latter cannot be accessed given their confidential nature. Nonetheless, the list prices are relevant in this context as public authorities also use list prices of other countries when they apply EPR (solely the EPR legislation in Germany provides for the use of discounted prices [
13]).
4 Fourth, calculation of the average European prices was based on data expressed in Euros. In non-Euro countries, these data can be flawed due to exchange rate volatility. Finally, the availability of price data does not necessarily translate into actual patient access to medicines. A few countries indicate EPR-derived national prices in their price databases, even for medicines that have not been marketed (and the price database does not indicate their availability). In addition, medicines may have been launched but are not yet available to patients at a certain point in time due to shortages [
51] or because they are not affordable to patients in case of high out-of-pocket payments (e.g. as evidenced for cancer medicines [
52]). In other countries, patients can have access to a medicine but its price is not necessarily publicly available (e.g. prices for hospital medicines have not been published in Portugal since 2012 [
37]).